Table 1 Characteristics of patient at baseline
From: Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid
Total (n = 53) | |
|---|---|
Age (years) | |
Means (SD) | 65 (± 10) |
ECOG at sample | |
0 | 13 (25%) |
1 | 33(62%) |
2 | 7 (13%) |
Histology | |
Serous High grade | 47 ( 89%) |
Serous Low Grade | 4 (8%) |
Endometrioid | 2 (4%) |
Primary Tumor Location | |
Ovary | 44 (83%) |
Peritoneum | 5 (9%) |
Fallopian Tube | 4 (8%) |
International FIGO stage | |
II | 1 (2%) |
III | 32 (60%) |
IV | 20 (38%) |
Type of Sample | |
Laparoscopy | 46 (87%) |
Therapeutic paracentesis | 7 (13%) |
Status at sample | |
Primary laparoscopy | 35 (66%) |
Secondary laparoscopy | 11 (21%) |
Relapse | 7 (13%) |
Amount of peritoneal fluid at sample | |
Absence | 7 (13%) |
< 500 cc | 10 (19%) |
500 to 1000 cc | 12 (23%) |
> 1000 cc | 24 (45%) |